U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H38O6
Molecular Weight 422.5549
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOVASTATIN ACID

SMILES

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC

InChI

InChIKey=QLJODMDSTUBWDW-BXMDZJJMSA-N
InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20467214

Lovastatin is a cholesterol-lowering agent that belongs to the class of medications called statins. Alfred Alberts and his team at Merck discovered it in 1978 after screening only 18 compounds over 2 weeks. The agent, also known as mevinolin, was isolated from the fungi Aspergillus terreus. Research on this compound was suddenly shut down in 1980 and the drug was not approved until 1987. Interesting, Akira Endo at Sankyo Co. (Japan) patented lovastatin isolated from Monascus ruber four months before Merck. Lovastatin was found to be 2 times more potent than its predecessor, mevastatin, the first discovered statin. The primary uses of lovastatin is for the treatment of dyslipidemia and the prevention of cardiovascular disease. Lovastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid, a strong inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate. The conversion of HMG-CoA to mevalonate is an early step in the biosynthetic pathway for cholesterol. Lovastatin, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. The involvement of low-density lipoprotein cholesterol (LDL-C) in atherogenesis has been well documented in clinical and pathological studies, as well as in many animal experiments. Epidemiological and clinical studies have established that high LDL-C and low high-density lipoprotein cholesterol (HDL-C) levels are both associated with coronary heart disease. However, the risk of developing coronary heart disease is continuous and graded over the range of cholesterol levels and many coronary events do occur in patients with total cholesterol (Total-C) and LDL-C levels in the lower end of this range. Lovastatin immediate-release tablets have been shown to reduce elevated LDL-C concentrations. LDL is formed from very low-density lipoprotein (VLDL) and is catabolized predominantly by the high-affinity LDL receptor. The mechanism of the LDL-lowering effect of lovastatin immediate-release may involve both reduction of VLDL-C concentration, and induction of the LDL receptor, leading to reduced production and/or increased catabolism of LDL-C.

Originator

Curator's Comment: # Alfred Alberts and his team at Merck in 1978

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.64 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ALTOPREV

Approved Use

1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of: Myocardial infarction; Unstable angina; Coronary revascularization procedures; Coronary Heart Disease. Altoprev is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. Hyperlipidemia Altoprev is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).

Launch Date

1.01200318E12
Palliative
ALTOPREV

Approved Use

1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of: Myocardial infarction; Unstable angina; Coronary revascularization procedures; Coronary Heart Disease. Altoprev is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. Hyperlipidemia Altoprev is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).

Launch Date

1.01200318E12
Preventing
MEVACOR

Approved Use

After oral ingestion, lovastatin, which is an inactive lactone, is hydrolyzed to the lovastatin acid. This is a principal metabolite and an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. Lovastatin has been shown to reduce both normal and elevated low-density lipoprotein cholesterol (LDL-C).

Launch Date

5.5728E11
Primary
MEVACOR

Approved Use

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. MEVACOR is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.

Launch Date

5.5728E11
Secondary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.6 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.9 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
76.9 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
83 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Disc. AE: Aspartate aminotransferase increased, Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Aspartate aminotransferase increased (grade 2-4, 1.3%)
Alanine aminotransferase increased (grade 2-4, 1.3%)
Gastrointestinal disturbance (0.4%)
Rash (0.27%)
Myalgia (0.13%)
Myopathy (0.27%)
Arthralgia (0.13%)
Insomnia (0.13%)
Weight gain (0.13%)
Sources: Page: p.1082, 1083
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
DLT: Creatine phosphokinase increased, Aspartate aminotransferase increased...
Dose limiting toxicities:
Creatine phosphokinase increased (grade 4, 33.3%)
Aspartate aminotransferase increased (grade 2-3, 33.3%)
Alanine aminotransferase increased (grade 2-3, 33.3%)
Sources: Page: p.527
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
DLT: Creatine phosphokinase increased, Aspartate aminotransferase increased...
Dose limiting toxicities:
Creatine phosphokinase increased (grade 4, 28.6%)
Aspartate aminotransferase increased (grade 3, 14.3%)
Alanine aminotransferase increased (grade 3, 14.3%)
Sources: Page: p.527
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Insomnia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Myalgia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Weight gain 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Myopathy 0.27%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Rash 0.27%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Gastrointestinal disturbance 0.4%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Alanine aminotransferase increased grade 2-4, 1.3%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Aspartate aminotransferase increased grade 2-4, 1.3%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Alanine aminotransferase increased grade 2-3, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Aspartate aminotransferase increased grade 2-3, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Creatine phosphokinase increased grade 4, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Alanine aminotransferase increased grade 3, 14.3%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
Aspartate aminotransferase increased grade 3, 14.3%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
Creatine phosphokinase increased grade 4, 28.6%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
PubMed

PubMed

TitleDatePubMed
Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
1993 Nov 15
Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids.
1999 Apr
Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
1999 Mar
Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.
1999 Oct
Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis.
1999 Oct 10
Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture.
2000 Jun
Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of pneumocystis carinii f. sp. carinii.
2000 Jun
Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation?
2000 Mar
Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
2000 May
Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy.
2000 Nov
Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation.
2000 Oct 27
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.
2001 Apr
A new simvastatin (mevinolin)-resistance marker from Haloarcula hispanica and a new Haloferax volcanii strain cured of plasmid pHV2.
2001 Apr
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
2001 Apr
The widening role of statins: RAS signal transduction and drug-induced cytotoxicity in human leukemia: a commentary to 'interaction of cytosine arabinoside and lovastatin in human leukemia cells'.
2001 Aug
Interaction of cytosine arabinoside and lovastatin in human leukemia cells.
2001 Aug
[Practical questions for the expert].
2001 Feb
[Statins and stroke].
2001 Feb
[Statins: a major therapeutic breakthrough].
2001 Feb
Do HMG-CoA reductase inhibitors affect fibrinogen?
2001 Feb
Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.
2001 Feb 1
Fragmentation study of simvastatin and lovastatin using electrospray ionization tandem mass spectrometry.
2001 Jan
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.
2001 Jan
Statin trials in progress: unanswered questions.
2001 Jan
Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha).
2001 Jan 10
[The role of HDL in the prevention of cardiovascular events].
2001 Jan 21
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.
2001 Jun
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.
2001 Jun
A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.
2001 Mar
3-Hydroxy-3-methylglutaryl coenzyme A synthase-1 of Blattella germanica has structural and functional features of an active retrogene.
2001 Mar 15
What do the statin trials tell us?
2001 May
Statins--similarities and differences.
2001 May
Should all patients with cardiovascular disease receive statin therapy?
2001 May
Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins?
2001 May
Cholesterol ester accumulation: an immediate consequence of acute in vivo ischemic renal injury.
2001 May
Regulation of sterol regulatory element-binding proteins in hamster intestine by changes in cholesterol flux.
2001 May 18
Lovastatin controls signal transduction in vascular smooth muscle cells by modulating phosphorylation levels of mevalonate-independent pathways.
2001 May-Jun
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
2001 Spring
Patents

Sample Use Guides

Lovastatin is administered orally with the evening meal. Maximal daily dose for adults is 80 mg, maximal dose for children is 40 mg.
Route of Administration: Oral
In Vitro Use Guide
HMG-CoA reductase from rat liver microsomes was solubilizes and purified through the second ammonium sulfate precipitation. Prior to use, the enzyme was activated at 37C for 30 min. The reaction mix contained, in 100 uL: 0.14 M potassium phosphate buffer, pH 6.8; 0.18 M KCI; 3.5 mM EDTA, pH 7.0; 10 mM dithiothreitol; bovine serum albumin at 0.1 mg/ml; 0.02 uCi of [14C]HMG-CoA and 0.3 pg of partially purified enzyme (specific activity 100-150 nmol min-1 mg-1) with or without inhibitor. After 5-min incubation at 37C, the reaction was initiated with 0.2 mM NADPH. The reaction was terminated with 20 Al of 5 M HCL. After an additional incubation for 15 min at 370C to allow for complete lactonization of the product, mevalonate, the mixture was passed over a 0.5 X 5 cm column containing 100-200 mesh Bio-Rex, chloride form (Bio-Rad), which was equilibrated with distilled water. With this resin the unreacted [14C]HMG-CoA was adsorbed and the product, [14C]mevalonolactone, was eluted with 3 ml of distilled water directly into scintillation vials. After the addition of 10 ml of Aquasol II, radioactivities of the samples were measured in a scintillation counter. Lovastatin acid inhibited HMG-CoA reductase with Ki of 0.64 nM.
Name Type Language
LOVASTATIN ACID
Common Name English
LOVASTATIN IMPURITY B [EP IMPURITY]
Common Name English
MEVINOLINIC ACID
Common Name English
MSD-803 ACID
Code English
(.BETA.R,.DELTA.R,1S,2S,6R,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-.BETA.,.DELTA.-DIHYDROXY-2,6-DIMETHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-1-NAPHTHALENEHEPTANOIC ACID
Systematic Name English
MK-819
Code English
HYDROXYACID LOVASTATIN [EP IMPURITY]
Common Name English
1-NAPHTHALENEHEPTANOIC ACID, 1,2,6,7,8,8A-HEXAHYDRO-.BETA.,.DELTA.-DIHYDROXY-2,6-DIMETHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-, (.BETA.R,.DELTA.R,1S,2S,6R,8S,8AR)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1655
Created by admin on Wed Jul 05 23:34:03 UTC 2023 , Edited by admin on Wed Jul 05 23:34:03 UTC 2023
Code System Code Type Description
DRUG BANK
DB03785
Created by admin on Wed Jul 05 23:34:03 UTC 2023 , Edited by admin on Wed Jul 05 23:34:03 UTC 2023
PRIMARY
FDA UNII
5CLV35Y90C
Created by admin on Wed Jul 05 23:34:03 UTC 2023 , Edited by admin on Wed Jul 05 23:34:03 UTC 2023
PRIMARY
CAS
75225-51-3
Created by admin on Wed Jul 05 23:34:03 UTC 2023 , Edited by admin on Wed Jul 05 23:34:03 UTC 2023
PRIMARY
PUBCHEM
64727
Created by admin on Wed Jul 05 23:34:03 UTC 2023 , Edited by admin on Wed Jul 05 23:34:03 UTC 2023
PRIMARY
EPA CompTox
DTXSID20873334
Created by admin on Wed Jul 05 23:34:03 UTC 2023 , Edited by admin on Wed Jul 05 23:34:03 UTC 2023
PRIMARY
NCI_THESAURUS
C77442
Created by admin on Wed Jul 05 23:34:03 UTC 2023 , Edited by admin on Wed Jul 05 23:34:03 UTC 2023
PRIMARY
CHEBI
82985
Created by admin on Wed Jul 05 23:34:03 UTC 2023 , Edited by admin on Wed Jul 05 23:34:03 UTC 2023
PRIMARY